Matthew Gall

CIK 1816194 · Chief Financial Officer · last filed 2026-05-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.24M

Companies

3

Total Filings

16

Lifetime Open-Market Net

-$21.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TNGX Chief Financial Officer 40,000 $30.94 $1.24M $0 1 2026-05-05
KLRS Chief Financial Officer $4.33 $0 2 2026-03-20
iTeos Therapeutics, Inc. (ITOS) Delisted Chief Financial Officer 0 $10.15 $0 -$21.3K 13 2025-08-29

Recent Filings · Page 2 of 2

16 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2022-03-14 iTeos Therapeutics, Inc. (ITOS) Delisted Grant (A) $0 EDGAR
2021-12-28 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −5,000 -$232.2K EDGAR
2021-10-12 iTeos Therapeutics, Inc. (ITOS) Delisted Exer (M) +14,429 $88.9K EDGAR
2021-06-25 iTeos Therapeutics, Inc. (ITOS) Delisted Grant (A) $0 EDGAR
2021-06-16 iTeos Therapeutics, Inc. (ITOS) Delisted Buy (P) +5,000 $130.4K EDGAR
2021-03-03 iTeos Therapeutics, Inc. (ITOS) Delisted Grant (A) $0 EDGAR
Showing 1116 of 16
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.